Verismo Therapeutics, a clinical-stage company specializing in CAR-T therapies, has initiated the dosing of the first patient in their STAR-101 clinical trial.

This article summarized the latest R&D progress of Vardenafil hydrochloride, the Mechanism of Action for Vardenafil hydrochloride, and the drug target R&D trends for Vardenafil hydrochloride.

BET (Bromodomain and Extra-Terminal) proteins play a crucial role in the regulation of gene expression in the human body.

Viking Therapeutics, Inc. has recently commenced a Phase 2 clinical evaluation of VK2735.

This article summarized the latest R&D progress of Valrubicin, the Mechanism of Action for Valrubicin, and the drug target R&D trends for Valrubicin.

Atamyo Therapeutics proclaimed that the FDA has given the green light for its ATA-100 IND application to advance into a Phase 1b/2b clinical study.

Bcl-2 inhibitors can be used alone to kill cancer cells or can be used in combination with other drugs to increase the sensitivity of cancer cells to drugs.

VBI Vaccines Inc. publicized that its strategic HBV collaborator, Brii Biosciences announced preliminary group-level unmasked 36-week data from a mid-term examination of a randomly assigned, placebo-controlled, and double-concealed Phase 2 investigation of BRII-179 (VBI-2601).

This article summarized the latest R&D progress of Naxitamab, the Mechanism of Action for Naxitamab, and the drug target R&D trends for Naxitamab.

Johnson's Janssen Pharmaceutical Companies have disclosed encouraging preliminary findings from the tri-modality Phase 3 MARIPOSA-2 trial.

The Ataxia telangiectasia and Rad-3 related protein kinase (ATR) is a member of the PIKK protein kinase family, and it is involved in numerous complex DNA damage repair mechanisms.

This article summarized the latest R&D progress of Tucatinib, the Mechanism of Action for Tucatinib, and the drug target R&D trends for Tucatinib.